2:26 PM
 | 
Jun 13, 2018
 |  BC Extra  |  Clinical News

Lilly planning Phase III trials for Olumiant in lupus

Eli Lilly and Co. (NYSE:LLY) said it plans to start this year Phase III testing of Olumiant baricitinib to treat systemic lupus erythematosus (SLE) after reporting that the higher dose of the drug met the primary endpoint in a Phase II trial in the indication. Lilly presented the data at...

Read the full 228 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >